Leadership

Kevin Ness

Kevin Ness

CEO of Inscripta

Kevin Ness is the chief executive officer of Inscripta, a gene-editing technology company. Under his leadership, the company is liberating the scientific community by giving them a clear path to pursue new research and discoveries. Inscripta will provide full solutions essential for forward cell-engineering, including a family of CRISPR enzymes (called MADzymes), custom nucleases for researchers and commercial partners, and a full suite of gene-editing tools (instruments, reagents, and software) that will significantly increase the speed and efficiency of multiplexed, precision gene editing using a novel platform.

One of the most respected leaders at the forefront of genome engineering technologies, Kevin specializes in turning rapidly commercializing early stage ideas into successful ventures developing new paradigms to measure complex biological information at unprecedented resolution. He previously founded and built two groundbreaking companies in the genome reading space, QuantaLife and 10x Genomics. A mechanical engineer, he is a true tool builder at heart, and has committed his life to building the best-in-class solutions for biologists. A native of California, he earned his bachelor’s and master’s degree in mechanical engineering from University of California Santa Barbara and his doctorate in mechanical engineering from Stanford University.

Jason T. Gammack

Jason T. Gammack

Chief Commercial Officer

Jason T. Gammack is the chief commercial officer of Inscripta. A 25-year veteran of life sciences commercial operations, Jason will leverage his experience at leading biotechnology companies to design and oversee Inscripta’s sales, marketing, business development, and customer support operations. Jason has spent his career developing product and customer engagement strategies for some of the life science industry’s most preeminent brands. He was most recently at QIAGEN, where he led the development of the life science portfolio and go-to-market strategy as the vice president of the life science business area. Prior to QIAGEN, Jason developed commercialization growth strategies as an executive at Ingenuity Systems, a leading bioinformatics company acquired by QIAGEN in 2013. He has also held senior leadership roles at Sigma-Aldrich (SIAL), Life Technologies (LIFE), Affymetrix (AFFX), and Promega Corporation.

Michael Graige

Michael Graige

Chief Technical Officer

Michael brings over 20 years of experience in technology and product development, having led teams that developed and commercialized foundational reagent and consumable products for Illumina’s microarray and next generation sequencing platforms.  Prior to Illumina, Michael held positions at BioSite Diagnostics and the University of California.  He brings a broad background in measurement science, surface modification, process engineering, device fabrication, and cross-functional team leadership.  He holds a PhD in Chemical Physics from the University to California, San Diego. Michael is motivated to provide the scientific community with DNA editing tools to responsibly advance research, applied, and clinical markets.

Dianna Devore

Dianna DeVore

General Counsel

Dianna is General Counsel of Inscripta, specializing in product protection strategies, transactional law and patent enforcement for life science companies. Dianna was previously Senior Vice President of Intellectual Property and Legal Affairs at Ariosa Diagnostics, Inc., acquired by Roche Molecular Systems in 2015. Dianna has been legal and IP counsel for various companies including Complete Genomics, Cambridge Antibody Technology (a wholly-owned subsidiary of AstraZeneca) and Elan Pharmaceuticals. In 2002, Dianna co-founded the Australian Stem Cell Centre (ASCC) in Melbourne, Australia, the first Australian Biotechnology Centre of Excellence. At the ASCC, Dianna was responsible for oversight of all operational, corporate, legal and intellectual property activities.

Erik Warnecke

Erik Warnecke

VP Finance

Erik has an extensive financial and accounting background spanning fifteen years and specializes in turning complex financial data into meaningful information for effecting decision making. He has built high-performing teams to provide robust, effective analysis and reporting at each step in his career. His expertise includes financing, controls and compliance, finance and treasury management, SEC and financial reporting and investor relations. Prior to Inscripta, Erik served as Controller at Metropolitan Merchant Capital and played a senior financial reporting role during ZAYO’s IPO in 2014. Erik began his career in public accounting at Ernst & Young. He earned B.S. degrees in Accounting and Finance at Indiana University-Bloomington and his CPA certification in 2002.

Todd Rubano

Todd Rubano

VP Software

Todd has been involved in leading teams of engineers, software developers and IT specialists to automate and integrate high production genomics labs for over 20 years. He specializes in using a systems engineering approach to functionally integrate lab robotics, data tracking systems (LIMS) and business systems into a seamless environment enabling lab technicians and R&D scientists to excel in achieving consistent and rapid results. Todd has been involved in the startup through production phases of operations at genomics focused companies including Myriad Genetics, Illumina and Ariosa Diagnostics (now part of Roche Sequencing Systems).

Paul Hardenbol

Paul Hardenbol

VP Biology

Paul has developed products in the biotech field for over 20 years and has significant experience in bringing novel biochemistry to market for genomic applications. In his role at Inscripta, Paul leads enzyme engineering, cell biology and the development of gene editing tools. Paul holds a PhD in Biomedical Sciences from the University of Texas, Houston, and founded ParAllele Bioscience (acquired by Affymetrix in 2005.) Other past positions include Senior Director of Biochemistry at 10X Genomics, and Fellow at Pacific Biosciences.

Don Masquelier

Don Masquelier

VP Engineering

Don has a passion for building revolutionary tools for the Life Sciences community and has lead Engineering teams that have produced instruments currently changing the way science is done. As a previous Co-Founder of Quantalife and a former Director of Engineering for 10X Genomics he will continue innovate and build Best-in-Class tools for use with Inscripta technologies, moving applications for protein, pathway, and genome engineering to new levels.

Board of Directors

Michael Graige

John Stuelpnagel

Chairman

John Stuelpnagel has been Chairman of Inscripta since March 2017. In addition, John co-founded and was Executive Chairman of Ariosa from 2010 to 2015 when the company was acquired by Roche. He was also the Chairman of Sequenta from 2010 to 2015 when that company was merged with Adaptive Biotechnologies where he continues as a Member of the Board. Previously, John co-founded Illumina, Inc. and was instrumental in making Illumina one of the most successful life science companies. During his 12 years at Illumina, John served as the company’s first CEO and most recently served as COO. Prior to Illumina, John was a venture capitalist at CW Group. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.

Michael Graige

Bryan Roberts

Board of Directors

Bryan Roberts, Ph.D. has served on the Board of Directors since March of 2017. Bryan joined Venrock as a Kauffman Fellow in 1997. He is based in Venrock’s Palo Alto office and focuses on a broad range of healthcare investments. Bryan is currently Chairman of the Board of Directors of Achaogen (NASDAQ: AKAO), Castlight Health (NYSE: CSLT), Ironwood Pharmaceuticals (NASDAQ: IRWD), and Kyruus and also serves on the Board of several other companies, including 10X Genomics, Doctor on Demand, Grand Rounds, Intarcia, and Zeltiq (NASDAQ: ZLTQ). Past investments include Ariosa Diagnostics (acquired by Roche), athenahealth (NASDAQ: ATHN), CodeRyte (acquired by 3M), Ikaria (acquired by Madison Dearborn), Illumina (NASDAQ: ILMN), and Sirna Therapeutics (acquired by Merck). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and is the only healthcare investor to rank on Forbes’ Midas List six times, 2008 – 2014. Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.

Michael Graige

Roger Wyse

Board of Directors

Dr. Wyse is a Managing Partner of Spruce Capital Partners and BAR Capital Management. Previously he was a Managing Director at Burrill & Company. He joined Burrill in 1998 and led the development of the agriculture, food, nutraceuticals, and industrial biotech venture activities. He left Burrill in November 2013 to cofound Spruce Capital Partners which currently serves as the co-manager of Malaysian Life Sciences Capital Fund (MLSCF) and MLS Capital Fund II.

Prior to joining Burrill, Dr. Wyse served for five years as Dean of the College of Agricultural and Life Sciences at the University of Wisconsin-Madison, as Dean of Research at Cook College, Rutgers University, and as Director of the New Jersey Agricultural Experiment Station from 1986 to 1992.

Dr. Wyse is Co-Chairman of MLSCF and is a member of the International Advisory Panel for Biotechnology (BioIAP) and the Global Science and Innovation Advisory Council (GSIAC) for the Prime Minister of Malaysia, as well a member of the EU-based Knowledge Economy Network Advisory Board, among others. Dr. Wyse received a BS degree in Agronomy from Ohio State University and a PhD in Plant Physiology from Michigan State University.

Kevin Ness

Kevin Ness

Board of Directors

Kevin Ness is the chief executive officer of Inscripta, a gene-editing technology company. Under his leadership, the company is liberating the scientific community by giving them a clear path to pursue new research and discoveries. Inscripta will provide full solutions essential for forward cell-engineering, including a family of CRISPR enzymes (called MADzymes), custom nucleases for researchers and commercial partners, and a full suite of gene-editing tools (instruments, reagents, and software) that will significantly increase the speed and efficiency of multiplexed, precision gene editing using a novel platform.

One of the most respected leaders at the forefront of genome engineering technologies, Kevin specializes in turning rapidly commercializing early stage ideas into successful ventures developing new paradigms to measure complex biological information at unprecedented resolution. He previously founded and built two groundbreaking companies in the genome reading space, QuantaLife and 10x Genomics. A mechanical engineer, he is a true tool builder at heart, and has committed his life to building the best-in-class solutions for biologists. A native of California, he earned his bachelor’s and master’s degree in mechanical engineering from University of California Santa Barbara and his doctorate in mechanical engineering from Stanford University.